Andreas Struengmann

In 2005, Andreas Struengmann and twin brother Thomas sold their generic drugmaker Hexal (plus a stake in Eon Labs) to Novartis for some $7 billion. They cofounded Hexal in 1986. The company launched successful versions of the cholesterol-lowering drug simvastatin.The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.Their venture portfolio includes Germany's BioNTech and Uruguay's Mega Pharma, initially a joint venture with Argentine billionaire Alberto Roemmers.In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.